Listen

Description

December 9, 2025

“Cancer, above all other diseases, has countless secondary causes. But, even for cancer, there is only one prime cause. The prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar.”— Otto Warburg, Nobel Laureate, 1956

“Everyone should know that most cancer research is largely a fraud, and that the major cancer research organizations are derelict in their duties to the people who support them.”— Linus Pauling, Two-time Nobel Prize winner

“The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon should be turned toward conquering this dread disease.”— Richard Nixon, signing the National Cancer Act, 1971

[2024: U.S. crosses 2 million new cancer cases for the first time. Colorectal cancer now #1 killer of men under 50. Gen X and Millennials developing cancer at rates never seen in human history]

[Part 5 of 6]

New parts publish every Tuesday and Thursday at 10AM EST

Otto Warburg knew.

In 1924, the German biochemist discovered that cancer cells ferment glucose even when oxygen is abundant. Every normal cell on Earth uses oxygen to generate energy efficiently through respiration. Cancer cells don’t. They revert to an ancient, primitive pathway that yields one-eighteenth the energy output.

This made no evolutionary sense. Why would cells choose such catastrophic inefficiency?

Warburg tested carcinomas, sarcomas, lymphomas. The pattern held universally. Every tumor exhibited this metabolic aberration. He spent three decades refining his observations, accumulating evidence across laboratories and continents.

In 1956, he delivered his verdict: “Cancer, above all other diseases, has countless secondary causes. But, even for cancer, there is only one prime cause. The prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar.”¹

He had identified the origin.

They buried him.

The DNA Seduction (1953-1970s)

Watson and Crick discovered DNA’s double helix in 1953. The structure was elegant, the implications profound. Biology became information science. The “Central Dogma” captured imaginations: DNA → RNA → Protein. If life was fundamentally about hereditary information, then disease must originate from corrupted genetic code.²

Cancer researchers abandoned metabolism for genetics. Warburg’s Nobel-winning discovery became a footnote. The Warburg Effect was dismissed as an adaptive consequence of rapid growth, not causation.

This wasn’t purely scientific. It was seduction.

DNA was sexy. DNA was patentable. DNA justified infinite complexity and infinite research budgets. Mitochondrial metabolism was yesterday’s science, associated with pre-molecular biology. Researchers who pursued metabolic causes found grant applications rejected, papers dismissed, careers stalled.

The field aligned around the Somatic Mutation Theory (SMT): cancer is a genetic disease caused by sequential random mutations in nuclear DNA. Cells accumulate mutations through environmental damage, replication errors, or inherited predisposition. When enough “hits” accumulate in growth-regulating genes, normal cells transform into malignancies.³

The theory was elegant, comprehensive, and wrong.

But it was profitable. So it became dogma.

Nixon’s $100 Billion Con (1971)

President Richard Nixon signed the National Cancer Act in 1971, declaring a “War on Cancer” with lunar landing confidence. America had conquered the moon through targeted engineering. Cancer would fall the same way.⁴

Billions flowed into the National Cancer Institute. The funding mechanisms, grant review processes, and institutional incentives all aligned around SMT. Genetic research was the consensus. Metabolic proposals were antiquated throwbacks.

The consequences calcified quickly:

Metabolic research was systematically defunded. Academic departments focused on molecular genetics to secure grants. Pharmaceutical companies invested in targeted genetic therapies with patent protection. The “complexity narrative” justified continuous budget expansion.

By the 1980s, the genetic approach had achieved total institutional capture. To question SMT was career suicide.

Fifty years later, the mortality statistics tell the story. Adjusted for age and earlier detection, five-year survival for metastatic cancers shows negligible improvement. Glioblastoma multiforme, the most common brain cancer, has the same prognosis in 2024 as it did in 1970.⁾

The War on Cancer failed.

But the edifice stands because the edifice is profitable.

The Economics: You Can’t Patent Fasting

Genomic sequencing revealed that tumors harbor hundreds or thousands of mutations, varying wildly within single specimens. Instead of questioning whether these mutations were cause or consequence, the field doubled down.⁚

Complexity justified expansion:

* Genomic profiling services: $5,000-$15,000 per tumor

* Targeted therapies: $100,000-$300,000 per year

* Immunotherapies: $150,000+ annually

* Combination protocols: multiplicative cost escalation

Pharmaceutical companies invested billions developing drugs targeting specific mutations. Each drug received patent protection. Each mutation profile required different treatments. The complexity created infinite market segmentation.š⁰

Now consider the alternative:

* Ketogenic diet: unpatentable, $20-50 daily

* Intermittent fasting: free

* High-dose vitamin C: $30-100 monthly

* Repurposed metabolic drugs: generic pennies per dose

The return on investment for metabolic research approaches zero. A pharmaceutical company funding a ketogenic diet study might prove a cheap intervention works, obliterating markets for expensive drugs.

This creates structural filters. Metabolic proposals are rejected as “too simple” or “lacking novelty.” Grant reviewers trained in the genetic paradigm view metabolism as reductionist. The NCI’s funding priorities reflect institutional capture.¹¹

You can’t patent fasting.

So metabolic therapies remain fringe, accessible only to patients willing to research outside standard protocols.

Life-saving interventions are dismissed because they threaten revenue streams.

The Smoking Gun: Nuclear Transfer Experiments

While the genetic paradigm achieved dominance, a series of elegant experiments were quietly demolishing its foundations.

Nuclear cytoplasm transfer experiments test where “cancer” resides: in the nucleus (DNA) or the cytoplasm (mitochondria and metabolic machinery).

The protocol is straightforward:

Experiment 1: Remove the nucleus from a cancer cell containing mutated DNA. Transfer it into a healthy cell whose nucleus has been removed, leaving normal mitochondria and cytoplasm intact.

If SMT is correct and cancer is fundamentally genetic, the mutated nucleus should produce cancer regardless of cellular context.

Result: The cells developed normally. No tumors formed. Mice injected with these cells remained healthy.š²

The cancer cell’s “mutated” nucleus, when placed in a metabolically healthy cytoplasm with functional mitochondria, was suppressed completely. Normal mitochondria rescued the supposedly cancer-driving mutations.

Experiment 2: Transfer a normal, unmutated nucleus into a cancer cell’s cytoplasm with dysfunctional mitochondria.

If genetics drive cancer, this should produce normal cells.

Result: The cells became malignant. Tumors formed.š³

A healthy nucleus placed in metabolically dysfunctional cytoplasm with damaged mitochondria produced cancer.

The Replication Pattern

These weren’t isolated findings. The experiments were performed across decades by independent research groups:

* McKinnell et al. (1969): Frog renal tumor nuclear transfersš⁴

* Mintz and Illmensee (1975): Teratocarcinoma nuclear transfers producing normal miceš⁾

* Hochedlinger et al. (2004): Melanoma nuclear transfers via somatic cell nuclear transferš⁜

* Seyfried and collaborators (2010s): Systematic replication demonstrating mitochondrial primacyš⁡

The pattern held universally: driver mutations in the nucleus are insufficient to cause cancer…



This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit tatsuikeda.substack.com/subscribe